Similar efficacy-toxicity relationships have emerged for molecularly targeted therapies, including better outcomes in the setting of high-grade cutaneous reactions from epidermal growth factor receptor (EGFR) inhibitors (6–10) or hypertension from antiangiogenic agents (11, 12). Here, EGFR is linked to hypertensive disorder.